Loading
A phase 2 trial of colorectal cancer (CRC) screening in colorectal cancer, run by Jubaan Ltd., now recruiting.
Evaluation of Gixam's Performance in a FIT Negative Population is a phase 2 interventional study registered as NCT06612281 by Jubaan Ltd., with 400 participants planned, started 2024-11-01 and due to reach its primary completion in 2025-03-30. Interventions recorded: colorectal cancer (CRC) screening and Colonoscopy after bowel cleansing.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/